Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Daily

Download Data

Monte Rosa Therapeutics Inc Earnings Yield on June 03, 2024: -55.45%

Monte Rosa Therapeutics Inc Earnings Yield is -55.45% on June 03, 2024, a -82.86% change year over year. The earnings yield represents the earnings per share as a percentage of the market price per share. It is calculated by dividing income after tax by the market capitalization. This ratio provides insight into the relative value of a company's earnings in relation to its market value. A higher earnings yield may indicate a relatively undervalued stock.

Monte Rosa Therapeutics Inc 52-week high Earnings Yield is -29.49% on June 16, 2023, which is 46.82% above the current Earnings Yield.
Monte Rosa Therapeutics Inc 52-week low Earnings Yield is -42,599.41% on March 11, 2024, which is -76,731.53% below the current Earnings Yield.
Monte Rosa Therapeutics Inc average Earnings Yield for the last 52 weeks is -388.83%.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends